CoreRx is a CDMO with end-to-end capabilities and specializes in small market molecules and difficult-to-formulate NCEs and 505(b)(2) pathways

Headquarters: Clearwater, FL
Status: Active
Industry: Pharma Services
Investment Date: January 2021
Visit Site

Investment Thesis

QHP partnered with CoreRx to develop a CDMO with end-to-end capabilities that could fill the gap of small batch manufacturers focusing on niche drug formulations with capacity

QHP Value Enhancement